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Objectives. This study attempted to determine whether cardiac 
sympathetic reinnervation occurs late after orthotopic heart 
transplantation. 
Background. Metaiodobenzylguanidine (MIBG) is taken up by 
myocardial sympathetic nerves. Iodine-123 (I-123) MIBG cardiac 
uptake reflects intact myocardial sympathetic innervation of the 
heart. Cardiac transplant recipients do not demonstrate 1-123 MIBG 
cardiac uptake when studied <6 months from transplantation. 
However, physiologic and biochemical studies suggest hat sympa- 
thetic reinnerv'ation of the heart can occur > 1 year after transplan- 
tation. 
Methods. We performed serial cardiac 1-123 MIBG imaging in 
23 cardiac transplant recipients early (<1 year) and late (>1 
year) after operation. In 16 subjects transmyocardial norepineph- 
rine release was measured late after transplantation. 
Results. No subject had visible 1-123 MIBG uptake on imaging 
<1 year after transplantation. However, 11 (48%) of 23 subjects 
developed visible cardiac 1-123 MIBG uptake l to 2 years after 
transplantation. Only 3 (25%) of 12 subjects with a pretransplan- 
tation diagnosis of idiopathic cardiomyopathy demonstrated 1-123 
MIBG uptake compared with 8 (73%) of 11 with a pretransplan- 
tation diagnosis of ischemic or rheumatic heart disease (p = 
0.04). All 10 subjects with a net myocardial release of norepineph- 
rine had cardiac 1-123 MIBG uptake; all 6 subjects without a net 
release of norepinephrine had no cardiac 1-123 MIBG uptake. 
Conclusions. Sympathetic reinnervation of the transplanted 
human heart can occur > 1 year after operation, as assessed by 
1-123 MIBG imaging and the transmyocardial release of norepi- 
nephrine. Reinnervation is less likely to occur in patients with a 
pretransplantation diagnosis of idiopathic cardiomyopathy than 
in those with other etiologies of congestive heart failure. 
(JAm CoU Cardiol 1995;25:927-31) 
Orthotopic ardiac transplantation is now the treatment of 
choice for suitable patients with end-stage congestive heart 
failure due to ischemic, idiopathic or other causes. Most 
transplant recipients have a marked improvement in the 
quality of life and enjoy 1- and 5-year survival rates of 80% to 
90% and 70% to 80%, respectively (1-3). One of the major 
impediments o further improvement in graft and patient 
survival is graft coronary vasculopathy (4-8). A particular 
problem with graft coronary vasculopathy is the lack of signs 
and symptoms ofmyocardial ischemia in transplant recipients. 
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The typical orthotopic ardiac transplantation involves exci- 
sion of the entire recipient heart except for the posterior atrial 
walls, to which the donor heart is grafted. The donor sinoatrial 
node provides the necessary pacemaker activity in the trans- 
planted heart. However, there is severance of autonomic 
nerves to the grafted heart (1,9). For this reason, silent 
myocardial ischemia can develop in the setting of graft coro- 
nary vasculopathy. To identify the development of graft vas- 
culopathy, most cardiac transplant programs perform annual 
coronary angiography. 
A recent report of chest pain in cardiac transplant recipi- 
ents suggests hat reinnervation fthe grafted heart might be 
possible (10). In addition, an imaging study demonstrated 
uptake of norepinephrine analogues labeled with positron 
radionuclides in transplant recipients late after operation (11). 
We explored the phenomenon ofcardiac reinnervation using 
radioiodinated metaiodobenzylguanidine (MIBG) imaging, 
which is an analog of the adrenergic false neurotransmitter 
guanethidine and is taken up by myocardial sympathetic nerves 
in a manner similar to norepinephrine (12-14). This uptake 
reflects cardiac adrenergic neuron integrity and function 
(13,15). We recently found (16) no evidence of cardiac iodine- 
123 (I-123) MIBG uptake in cardiac transplant recipients up to 
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5 months after transplantation, suggesting a lack of early 
cardiac reinnervation. However, cardiac autonomic reinnerva- 
tion is likely to be a slow process. We now report our findings 
of 1-123 MIBG imaging in cardiac transplant recipients 1to 3 
years after transplantation i  an effort to document he 
presence or absence of cardiac reinnervation. 
Methods  
Patients. Twenty-three consecutive patients with New 
York Heart Association functional classes III and IV conges- 
tive heart failure underwent orthotopic ardiac transplantation 
at the University of California San Francisco between 1989 and 
1992. All 23 patients agreed to participate in this research 
study. Ten of these patients have previously been reported on 
(16). The indications for orthotopic ardiac transplantation 
were idiopathic dilated cardiomyopathy (n = 12), ischemic 
cardiomyopathy (n = 10), and congestive heart failure due to 
rheumatic heart disease (n = 1). The study protocol and 
consent form were approved by the University of California 
San Francisco Committee on Human Research. All patients 
provided written informed consent. 
All patients received graft rejection prophylaxis with cyclo- 
sporine, prednisone and azathioprine. Cyclosporine-associated 
hypertension was generally treated with diuretic drugs and a 
calcium channel blocking agent. Routine surveillance ndo- 
myocardial biopsies were performed after cardiac transplanta- 
tion to rule out occult graft rejection. All patients underwent 
radionuclide ventriculography after transplantation to assess 
cardiac function. Patients also had annual exercise thallium 
scintigraphy and coronary angiography to rule out occult graft 
vasculopathy. Respiratory gas analysis was also performed at 
rest and at peak exercise. 
Iodine-123 MIBG imaging, Unlabeled MIBG was obtained 
from the University of Michigan and was radioiodinated by 
solid-phase ammonium sulfate exchange (15). Four to eight 
millicuries of 1-123 MIBG was injected as an intravenous bolus 
with patients in a relaxed, supine position. None of the patients 
were taking medications known to inhibit MIBG uptake. Serial 
dynamic imaging was performed at 30-s intervals, commencing 
just before the 1-123 MIBG injection and continuing for 
15 rain. The scintillation camera (Siemens Orbitor, equipped 
with a low energy all-purpose collimator) was positioned in the 
anterior projection. Late images were not obtained because 
our previous work (16) has demonstrated that the human heart 
has little if any significant extraneuronal uptake, and hence 
early 1-123 MIBG uptake is sufficient o demonstrate n uronal 
uptake. The presence or absence of 1-123 MIBG uptake was 
assessed qualitatively. The intraobserver and interobserver 
agreement for detection of myocardial 1-123 MIBG uptake was 
100%. Myocardial 1-123 MIBG uptake was quantified by 
measuring the heart/mediastinal r tio. In subjects with normal 
hearts at our institution, this ratio is 1.8 _+ 0.1 (16). No 
correction for lung background was made for the qualitative 
assessment of cardiac uptake because 19 of the subjects erved 
as their own control, and there was no difference in lung 
background between the studies performed. 
Nineteen patients underwent 1-123 M1BG imaging at 3.8 + 
0.8 and 15.4 + 4.7 months after cardiac transplantation. Two of 
these 19 patients also underwent imaging at 25 months. Two 
additional patients underwent 1-123 MIBG imaging at 13.5 _+ 
0.7 and 25.5 _+ 0.7 months after cardiac transplantation. One of 
these two patients also underwent imaging at 36 months. The 
final two patients underwent imaging only at 20 months after 
cardiac transplantation. No patients underwent imaging during 
active graft rejection of grade 1B or higher. All patients were 
clinically well and without symptoms of angina pectoris at the 
time of their MIBG imaging. 
Transmyocardial norepinephrine release. Transmyocar- 
dial norepinephrine r lease was measured in 16 patients 21 _+ 
9.6 months after cardiac transplantation. Rest and supine 
single blood samples were obtained from the ascending aorta 
and coronary sinus at the time of routine surveillance angiog- 
raphy and were analyzed for norepinephrine concentrations. 
These blood samples were immediately centrifuged at 
2,000 rpm for 15 min at 2 to 4°C. Plasma was separated and 
frozen at -70°C for later determination of norepinephrine 
concentrations u ing high pressure liquid chromatography with 
electrochemical detection (Smith Kline Beecham Laborato- 
ries). Transmyocardial norepinephrine r lease was calculated 
as coronary sinus norepinephrine minus aortic norepinephrine. 
The coefficient of variation for norepinephrine l vels was 
6,5%. 
Statistics. Potential characteristic differences before and 
after cardiac transplantation between patients with positive 
and negative MIBG uptake results were analyzed by the 
unpaired Student test. Potential differences in gender and 
disease status between patients with positive and negative 
MIBG uptake results were analyzed by the one-sided chi- 
square contingency table method; p < 0.05 was considered 
significant. 
Results 
Patients. Nineteen men and four women were studied 
(mean [_+SD] age 50 _+ 8.5 years) (Table 1). The mean left 
ventricular ejection fraction was 0.60 _+ 0.07 determined 21 _+ 
7 months after cardiac transplantation. Three of 23 patients 
had minor reversible apical myocardial perfusion defects on 
exercise thallium scintigraphy; the remaining 20 patients had 
normal thallium scan results. No patient had evidence of graft 
coronary occlusive disease on annual coronary angiography. 
Iodine-123 MIBG Imaging. None of 19 evaluable patients 
had visible cardiac uptake <5 months after cardiac transplan- 
tation (Fig. 1). Eleven (48%) of 23 patients demonstrated 
prominent anterior and basal myocardial 1-123 MIBG uptake 
at 1 to 2 years after cardiac transplantation (Fig. 1). The 1-123 
MIBG heart/mediastinal ratio for the 11 images showing 
uptake was 1.7 _+ 0.3; in 10 images without uptake this ratio 
was 1.2 _+ 0.1 (p < 0.001). The majority of patients with cardiac 
1-123 MIBG uptake had a pretransplantation diagnosis of 
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Table 1. Clinical Characteristics of 23 Study Patients Before and 
After Cardiac Transplantation 
No MIBG MIBG 
Uptake Uptake p 
(n = 12) (n = 11) Value 
Before cardiac transplantation 
Age (yr) 49.6 -+ 9.4 51.2 _+ 7.8 NS 
Gender (M/F) 9/3 10/1 NS 
Disease status 
Idiopathic 9 3 0.04 
Ischemic/rheumatic 3 8 
After cardiac transplantation 
Follow-up (mo) 22.4 + 8.8 19.5 + 4.3 NS 
Donor heart 
Age of donor (yr) 31.7 ± 10.8 36.0 _+ 12.9 NS 
Ischemic time (min) 153.7 + 35.8 174.5 ± 44.6 NS 
Average cyclosporine level 153.9 ± 7(I.2 122.1 -+ 46.0 NS 
(ng/ml)* 
Rejection grade IA 2 2 
Rejection ~ grade 1B 11 0 
Rest heart rate (beats/rain) 89.1 ± 9.8 90.5 + 12.1 NS 
Peak exercise heart rate 135.3 _+ 21.4 130.0 + 19.2 NS 
(beats/min) 
Peak exercise systolic blood I49.1 ± 16.5 160.1 -+ 22.6 NS 
pressure (mm Hg) 
Peak exercise oxygen 19.6 - 5.0 15.9 + 2.9 NS 
consumption (ml/kg per min) 
Left ventricular ejection fraction 0.61 _+ 0.08 0.58 ± 0.05 NS 
*Average cyclosporine trough whole-blood levels as determined atroutine 
phlebotomies for follow-up visits (measured by high performance liquid chro- 
matography). Data presented are mean value + SD or number of patients. F = 
female; M - male; MIBG - metaiodobenzylguanidine. 
ischemic ardiomyopathy or rheumatic heart disease (8 [73%] 
of 11). In the 12 patients without cardiac 1-123 MIBG uptake, 
3 (25%) had a pretransplantation diagnosis of ischemic car- 
Figure 1. Iodine-123 (I-123) metaiodobenzylguanidine (MIBG) scin- 
tigraphic images taken at 5, 10 and 15 rain after injection at 3 months 
and 1 year after transplantation i  an individual heart transplant 
recipient. After blood pool clearance there is an absence of 1-123 
MIBG myocardial localization at 3 months, which is present at 1 year 
after transplantation. S/P = status post. 
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Figure 2. Correlation between cardiac iodine-123 (I-123) metaiodo- 
benzylguanidine (MIBG) uptake and transmyocardial re ease of nor- 
epinephrine (NE). Positive norepinephrine values indicate net 
transmyocardial norepinephrine r lease. Solid bars = cardiac 1-123 
MIBG uptake; open bars - no cardiac 1-123 MIBG uptake. 
diomyopathy (Table 1), and 9 had idiopathic dilated cardiom- 
yopathy (p = 0.04). There were no other significant differences 
in characteristics before and after cardiac transplantation 
between patients with and without 1-123 MIBG uptake. (Table 
1). When only the 19 patients with serial images were analyzed, 
10 (53%) had evidence of late 1-123 MIBG cardiac uptake, 8 of 
whom had a pretransplantation diagnosis of ischemic cardio- 
myopathy or rheumatic heart disease. In contrast, seven (78%) 
of nine patients without 1-123 MIBG cardiac uptake had a 
pretransplantation diagnosis of idiopathic dilated cardiomyop- 
athy (p = 0.04). Two patients in each group (I-123 MIBG 
uptake present or absent) underwent late imaging when endo- 
myocardial biopsy results showed grade 1A rejection (Table 1). 
Transmyocardial norepinephrine release. Transmyocar- 
dial release of norepinephrine was determined in 16 subjects a
mean of 23 + 7.6 months (range 15 to 30) after cardiac 
transplantation (Fig. 2). All 10 patients with cardiac 1-123 
MIBG uptake demonstrated a net release across the heart. In 
contrast, all six patients without cardiac 1-123 MIBG uptake 
failed to demonstrate a net release of norepinephrine across 
the heart. 
3 months  
1 year 
!~!i~,~ ¸  ¸
D iscuss ion  
Iodine-123 MIBG Imaging. The presence of cardiac 1-123 
MIBG uptake in nearly 50% of our subjects indicates that 
autonomic reinnervation occurs frequently in the human trans- 
planted heart. Serial 1-123 MIBG scans in our subjects dem- 
onstrate that significant reinnervation is delayed because 1-123 
MIBG cardiac uptake is only demonstrable ->1 years after 
transplantation. In human transplanted hearts, cardiac sympa- 
thetic neurons are severed from their cell bodies in thoracic 
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and cervical ganglia. Norepinephrine stores in the cardiac 
nerve terminals are rapidly depleted because the biochemical 
machinery needed to synthesize norepinephrine must be trans- 
ported from the native ganglion to the nerve terminal by 
axonal transport (17,18). Intact adrenergic innervation of the 
heart is the principal determinant of myocardial norepineph- 
rine production (19,20). Metaiodobenzylguanidine has uptake 
and storage properties imilar to norepinephrine but is not 
metabolized by monoamine oxidase or catechol o-methyl 
transferase (12). Metaiodobenzylguanidine localizes to the 
adrenal medulla, adrenergic nerves and myocardium inseveral 
animal species, including humans (15,21,22). The presence of 
1-123 MIBG cardiac uptake late after cardiac transplantation 
provides evidence of autonomic reinnervation i  the trans- 
planted heart. 
Within 1 year of cardiac transplantation, the lack of cardiac 
autonomic reinnervation can be demonstrated by the repro- 
ducible attenuation of the heart rate response to exercise 
(23-26); low myocardial norepinephrine content (17,26-31); 
rarity of nerves seen in anatomic specimens of transplanted 
hearts (32,33); and lack of cardiac 1-123 MIBG uptake (16,34). 
Several lines of evidence support he finding that reinnervation 
occurs in the human transplanted heart >1 year after graft 
placement. First, cohort studies (25,26,30,31) have examined 
the physiologic response of cardiac transplant recipients to 
adrenergic stimuli "early" (2 to 14 months) and "late" (12 to 
102 months) after transplantation. These studies all demon- 
strate an improvement in the attenuation of the normal heart 
rate response to exercise (25,26), orthostasis (25), hand-grip 
exercise (26,30) or tyramine release (a chemical that stimulates 
norepinephrine r lease from intact sympathetic nerve termi- 
nals) (31) in patients late versus early after transplantation. 
Second, anginal chest pain has been reported in two patients 
36 months after cardiac transplantation (10). Both patients had 
angiographically confirmed graft coronary vasculopathy. Third, 
cohort studies have demonstrated a significant increase in 
cardiac norepinephrine r lease or spillover after exercise (26), 
hand-grip exercise (30) and tyramine administration (10,31) in 
patients late versus early after transplantation. Our data 
provide strong confirmation of the ability of the transplanted 
human heart to reinnervate, both in terms of the development 
over time of 1-123 MIBG uptake on cardiac images and in 
terms of the 100% correlation between the presence (or 
absence) of 1-123 MIBG uptake on cardiac images and the 
presence (or absence) of transmyocardial norepinephrine r - 
lease. 
In our protocol, we studied patients erially over time with 
multiple 1-123 MIBG scans. Patients therefore acted as their 
own controls, and we were able to document that 11 patients 
with early negative findings on 1-123 MIBG scans later had 
positive findings. Our study design differs from that of previ- 
ously mentioned studies, which did not perform serial exami- 
nations of their subjects. 
Our use of 1-123 MIBG scintigraphy also confirms previous 
work (11) with positron emission tomography to examine the 
question of cardiac graft reinnervation. Scbwaiger et al. (11) 
reported cardiac uptake of carbon-11 hydroxyephedrine 5.3_+ 
3.0 months after cardiac transplantation. Carbon-ll hy- 
droxyephedrine is a catecholamine analogue and its uptake in 
the heart, like MIBG, indicates the presence of intact sympa- 
thetic nerve terminals. The positron emission tomographic 
scan images howed uptake in the proximal anterior and septal 
walls of the heart, a finding consistent with our 1-123 MIBG 
scan images predominantly of the proximal anterior and basal 
myocardium. Thus, the pattern of reinnervation recapitulates 
the normal pattern of early sympathetic neuronal ingrowth and 
distribution in the heart (high neuronal density at the base and 
progressively less density toward the apex) (36). 
Although this study and previous studies have demon- 
strated that late reinnervation can occur in a significant 
proportion of cardiac transplant recipients, the clinical signif- 
icance of this phenomenon remains unknown. In our subjects, 
there was no difference in heart rate, systolic blood pressure or 
oxygen consumption at peak exercise between those patients 
who developed myocardial 1-123 MIBG uptake and those who 
did not (Table 1). Therefore, initial evidence of sympathetic 
reinnervation did not have physiologic functional conse- 
quences in our subjects. It is possible that physiologic onse- 
quences of reinnervation may be delayed from the first evi- 
dence of 1-123 MIBG uptake and that serial exercise tests with 
peak oxygen consumption determination may eventually be- 
come significant. 
Numerous questions remain regarding the phenomenon of
cardiac reinnervation. Among these is, "Do all transplanted 
hearts become reinnervated over time?" A surprising finding 
in our study was that 73% of patients who underwent trans- 
plantation for ischemic cardiomyopathy (n = 7) or rheumatic 
heart disease (n = 1) eventually had reinnervation of their 
heart compared with only 25% of those undergoing transplan- 
tation for idiopathic dilated cardiomyopathy (p = 0.04). The 
patient numbers are small, but this suggests that the underlying 
pathophysiology of heart failure might influence the kinetics 
and eventuality of reinnervation after cardiac transplantation. 
Autoantibodies against he beta~-adrenoceptor and against he 
adenosine diphosphate/adenosine triphosphate carrier in the 
inner mitochondrial membrane have been described in pa- 
tients with idiopathic dilated cardiomyopathy (36,37). Could 
patients with idiopathic ardiomyopathy beproducing antiau- 
tonomic neuronal antibodies? Patients with diabetes mellitus 
have been shown to produce antiautonomic neuronal antibod- 
ies (38). These patients develop an autonomic neuropathy and 
demonstrate decreased cardiac 1-123 MIBG uptake (13,39). 
Patients with idiopathic dilated cardiomyopathy have de- 
creased cardiac 1-123 MIBG retention (34). There may be a 
common link between the pathophysiology of cardiomyopathy 
and the relative lack of reinnervation after cardiac transplan- 
tation in this group of patients. A larger number of patients will 
be needed to determine with certainty whether there is a true 
difference in the reinnervation rates of patients with idiopathic 
versus ischemic cardiomyopathy after cardiac transplantation. 
Transmyoeardial norepinephrine r lease. In the present 
study, excellent correlation was found between myocardial 
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norepinephrine r lease and 1-123 MIBG uptake. Norepineph- 
fine release may indicate decreased reuptake or increased 
synthesis and release, or both. Whatever the mechanisms for 
higher norepinephrine concentration i the coronary sinus in 
patients with 1-123 MIBG uptake, norepinephrine release 
probably represents active myocardial norepinephrine metab- 
olism, providing further evidence for sympathetic reinnerva- 
tion. 
Conclusions. Our findings confirm the late reinnervation 
of the human heart after transplantation. Reinnervation occurs 
predominantly in the anterior and basal myocardium where 
adrenergic nerve density is greatest in the normal human heart. 
The functional consequences of a partially reinnervated heart 
are unknown. It appears that more transplant recipients with 
ischemic ardiomyopathy will have reinnervation of their heart 
than those with idiopathic dilated cardiomyopathy. 
We are grateful to Ronald Sutherland for preparation of the manuscript. 
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